The structure based drug design for controlling the innate immune response and interleukin-18 signaling.

MyD88是Toll样受体和IL-1/18信号通路中重要的接头分子。在这项研究中，我们试图根据我们确定的MyD88的蛋白质结构和蛋白质相互作用的研究结果来创建调节这些免疫信号反应的分子。在此研究期间，我们可以开发几种与含TIR结构域的分子直接进行蛋白质-蛋白质相互作用研究的方法。此外，我们还构建了含有显性阴性MyD88蛋白转导结构域的新分子（PTD-MyD88-DN）。我们将继续以MyD88为目标的药物开发。

MyD88 is the important adaptor molecule in the Toll like receptors and IL-1/18 signaling pathways. In this study, we tried to create the molecule, which regulate these immune signaling response, based on the results of our decided protein structure of MyD88 and protein interaction studies. In the duration of this research aid, we could develop the several methods of direct protein-protein interaction studies with the TIR domain containing molecules. Furthermore, we created the new molecule, protein transduction domain containing dominant negative formed MyD88 (PTD-MyD88-DN). We will continue the drug development that assumed MyD88 a target.